My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1176

    1.

    The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.

    Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL.

    Ann Intern Med. 2001 May 1;134(9 Pt 1):737-45.PMID: 11329231 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

    Fonseca V, Rosenstock J, Patwardhan R, Salzman A.

    JAMA. 2000 Apr 5;283(13):1695-702. Erratum in: JAMA 2000 Sep 20;284(11):1384. PMID: 10755495 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.

    Hershon KS, Hershon PM.

    Endocr Pract. 2000 Jan-Feb;6(1):20-5.PMID: 11419922 [PubMed - indexed for MEDLINE]Related articles

    5.

    Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

    Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW.

    J Clin Endocrinol Metab. 1998 Sep;83(9):3169-76.PMID: 9745421 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

    Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947. PMID: 11874944 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

    Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW.

    Diabetes Care. 1998 Sep;21(9):1462-9.PMID: 9727892 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

    Schwartz S, Raskin P, Fonseca V, Graveline JF.

    N Engl J Med. 1998 Mar 26;338(13):861-6.PMID: 9516220 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

    Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL.

    Clin Ther. 2000 Dec;22(12):1395-409.PMID: 11192132 [PubMed - indexed for MEDLINE]Related articles

    10.

    Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

    Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P.

    Diabetologia. 1996 Jun;39(6):701-9. Erratum in: Diabetologia 1996 Oct;39(10):1245. PMID: 8781766 [PubMed - indexed for MEDLINE]Related articles

    11.

    A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.

    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.

    Diabetes. 1999 Dec;48(12):2414-21.PMID: 10580431 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

    Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL.

    Am J Med. 2001 Jul;111(1):10-7.PMID: 11448655 [PubMed - indexed for MEDLINE]Related articles

    13.

    Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

    Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

    14.

    United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

    [No authors listed]

    Ann Intern Med. 1998 Feb 1;128(3):165-75.PMID: 9454524 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

    Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH.

    Clin Ther. 2003 Apr;25(4):1074-95.PMID: 12809958 [PubMed - indexed for MEDLINE]Related articles

    16.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    17.

    One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

    Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

    Diabetes Care. 2004 Jan;27(1):141-7.PMID: 14693980 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

    Lewin A, Lipetz R, Wu J, Schwartz S.

    Clin Ther. 2007 May;29(5):844-55.PMID: 17697903 [PubMed - indexed for MEDLINE]Related articles

    19.

    The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

    Diabetes Care. 1998 May;21(5):701-5.PMID: 9589227 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.

    Dailey GE 3rd, Mohideen P, Fiedorek FT.

    Clin Ther. 2002 Sep;24(9):1426-38.PMID: 12380634 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity